MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

IPSU

CAS No. : 1373765-19-5

MCE 站：IPSU

产品活性：IPSU是一种选择性，有口服活性和脑渗透性的OX2R拮抗剂，pK_i值为7.85。

研究领域：GPCR/G Protein  |  Neuronal Signaling

作用靶点：Orexin Receptor (OX Receptor)

In Vitro: Orexin receptor antagonists represent attractive targets for the development of drugs for the treatment of insomnia. IPSU binds rapidly and reaches equilibrium very quickly in binding and/or functional assays.

In Vivo: IPSU has low blood clearance, shows high maximal blood exposure and AUC after oral dosing. It exhibits an acceptable absolute oral bioavailability and a brain/blood concentration ratio that indicated favorable brain penetration. IPSU increases sleep when dosed during the mouse active phase (lights off); IPSU induces sleep primarily by increasing NREM sleep. IPSU shows a fast onset of action, with a clear increase in total sleep time during the first hour afterdosing. The effect lasts 4-5 h, after which time the total sleep time per hour is the same as on vehicle day .

相关产品：Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Neuronal Signaling Compound Library  |  Endocrinology Compound Library  |  Orally Active Compound Library  |  Orexin A (human, rat, mouse)  |  TCS-OX2-29  |  GSK1059865  |  SB-674042  |  TCS 1102  |  EMPA  |  SB-408124  |  Orexin B, human TFA  |  SB-649868  |  Orexin B, rat, mouse  |  Orexin receptor antagonist 2  |  OXA(17-33)  |  [Ala11,D-Leu15]-Orexin B(human)

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。